The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Angel Guerrero-Zotano
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Nisha Unni
Consulting or Advisory Role - AstraZeneca; Biotheranostics; Eisai; Immunomedics; Lilly; MacroGenics; Novartis; Sanofi
 
Adam Brufsky
Consulting or Advisory Role - Abbvie; Agendia; Bayer; bioTheranostics; Coherus Biosciences; Coherus Biosciences; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; General Electric; Gilead Sciences; Immunomedics; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen; Tyme
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
James Ross Waisman
No Relationships to Disclose
 
Eddy Shih-Hsin Yang
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Lilly; Strata Oncology
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst); Puma Biotechnology (Inst)
 
Iben Spanggaard
Stock and Other Ownership Interests - Genmab (I)
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Genentech (Inst); Genmab (Inst); Incyte (Inst); Loxo/Bayer (Inst); Loxo/Lilly (Inst); MSD (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Symphogen (Inst)
Travel, Accommodations, Expenses - Roche
 
Sonya A. Reid
Honoraria - Novartis
Research Funding - Agendia
 
Mark E. Burkard
Consulting or Advisory Role - LifeOmic; Novartis; Novartis; Pointcare genomics; Strata Oncology
Research Funding - Abbvie (Inst); Apollomics (Inst); Arcus Ventures (Inst); Elevation Oncology (Inst); Genentech (Inst); Loxo (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst); Strata Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent for a method to detect recombination events with CRISPR-mediated editing.; I have a patent for conducting expansion microscopy without specialized equipment.; I have patent for implantable/localized drug delivery device that can sample the tumor microenvironment and deliver drug.
Travel, Accommodations, Expenses - Lifeomic
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - MSD Oncology; Novartis Ireland Ltd.; Pfizer; Roche
Consulting or Advisory Role - G1 Therapeutics; MSD Oncology; Novartis Ireland Ltd.; Pfizer; Puma Biotechnology; Roche
Speakers' Bureau - Pfizer
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Abbvie; Daiichi Sankyo Europe GmbH; MSD; Novartis Ireland Ltd.; Pfizer; Roche
 
Ariella Hanker
Stock and Other Ownership Interests - Pfizer (I)
Research Funding - Takeda
 
Cynthia X. Ma
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Bayer; Biovica; Eisai; Gilead Sciences; Inivata; Jacobio; Natera; Novartis; Olaris; Philips Electronics; Puma Biotechnology; Sanofi; Seagen
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Ron Bose
Consulting or Advisory Role - Genentech
Research Funding - Puma Biotechnology (Inst)
 
Lisa DeFazio Eli
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Hans Wildiers
Honoraria - AstraZeneca (Inst); Eisai (Inst); MSD (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Lilly (Inst); Immutep (Inst); KCE (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Parexel (Inst); PSI (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer (Inst); Roche (Inst)